Viridian Therapeutics
Viridian Therapeutics Inc is an American clinical-stage biopharmaceutical company focused on the discovery and development of potential best-in-class antibody treatments for serious autoimmune and rare diseases. The company utilizes its specialized antibody engineering platform to develop differentiated therapies targeting insulin-like growth factor-1 receptor (IGF-1R), prominently featuring clinical candidates such as veligrotug and VRDN-008 for thyroid eye disease and related autoimmune conditions. Its core operations encompass preclinical antibody discovery, protein engineering, clinical trial management, and biotechnology research. As a clinical-stage biopharmaceutical enterprise, the company generates minimal commercial revenue and finances its operations through public equity financing and capital market funding. Viridian Therapeutics holds an emerging position in targeted immunological therapies. The company is headquartered in Waltham, Massachusetts, United States, and its common stock trades on the Nasdaq Global Select Market.
6 of the funds FundTelligence covers report a position in Viridian Therapeutics.
- Legal name
- Viridian Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 6
Funds holding Viridian Therapeutics
- DNB Bioteknologi — DNB · 2.27 % (full portfolio disclosed, September 2026)
- JPM Global Healthcare Fund — JPM · 0.32 % (full portfolio disclosed, June 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.3 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.04 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)